These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 15940882)

  • 21. [Peritoneal dissemination of ovarian cancer and tumor angiogenesis].
    Baba T; Mandai M; Fujii S
    Nihon Rinsho; 2004 Oct; 62 Suppl 10():467-70. PubMed ID: 15535289
    [No Abstract]   [Full Text] [Related]  

  • 22. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
    Grothey A; Ellis LM
    Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hoarseness during treatment with bevacizumab and other vascular endothelial growth factor signalling inhibitors.
    Wong H; Yau T; Man CW; Epstein RJ
    Acta Oncol; 2009; 48(8):1213-5. PubMed ID: 19863234
    [No Abstract]   [Full Text] [Related]  

  • 24. Challenges for patient selection with VEGF inhibitors.
    Longo R; Gasparini G
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):151-70. PubMed ID: 17370072
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting coagulation to the tumor microvasculature: perspectives and therapeutic implications from preclinical studies.
    Narazaki M; Tosato G
    J Natl Cancer Inst; 2005 May; 97(10):705-7. PubMed ID: 15900035
    [No Abstract]   [Full Text] [Related]  

  • 26. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy.
    Ferrara N; Hillan KJ; Novotny W
    Biochem Biophys Res Commun; 2005 Jul; 333(2):328-35. PubMed ID: 15961063
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of vascular endothelial growth factor genetic variability in cancer.
    Schneider BP; Radovich M; Miller KD
    Clin Cancer Res; 2009 Sep; 15(17):5297-302. PubMed ID: 19706811
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-angiogenic drugs to treat human disease: an interview with Napoleone Ferrara by Kristin H. Kain.
    Ferrara N
    Dis Model Mech; 2009; 2(7-8):324-5. PubMed ID: 19553691
    [No Abstract]   [Full Text] [Related]  

  • 29. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review.
    Eskens FA; Verweij J
    Eur J Cancer; 2006 Dec; 42(18):3127-39. PubMed ID: 17098419
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mammalian tumor xenografts induce neovascularization in zebrafish embryos.
    Nicoli S; Ribatti D; Cotelli F; Presta M
    Cancer Res; 2007 Apr; 67(7):2927-31. PubMed ID: 17409396
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of avastin in the management of recurrent glioblastoma.
    Sweet JA; Feinberg ML; Sherman JH
    Neurosurg Clin N Am; 2012 Apr; 23(2):331-41, x. PubMed ID: 22440876
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravitreal and intracameral bevacizumab to treat neovascular complications of retinopathy of prematurity.
    dell'Omo R; Kulkarni A; Franks WA
    Acta Ophthalmol; 2008 Sep; 86(6):698-700. PubMed ID: 18081905
    [No Abstract]   [Full Text] [Related]  

  • 33. In focus: non-small cell lung cancer: E1505.
    Clin Adv Hematol Oncol; 2007 Mar; 5(3):206-8. PubMed ID: 17519882
    [No Abstract]   [Full Text] [Related]  

  • 34. Angiogenesis of breast cancer.
    Schneider BP; Miller KD
    J Clin Oncol; 2005 Mar; 23(8):1782-90. PubMed ID: 15755986
    [No Abstract]   [Full Text] [Related]  

  • 35. Apoptotic and anti-angiogenic strategies in liver and gastrointestinal malignancies.
    Kountouras J; Zavos C; Chatzopoulos D
    J Surg Oncol; 2005 Jun; 90(4):249-59. PubMed ID: 15906369
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Angiogenesis suppressing therapy applied to malignant glioma].
    Takano S
    Gan To Kagaku Ryoho; 2009 Jun; 36(6):941-7. PubMed ID: 19579331
    [No Abstract]   [Full Text] [Related]  

  • 37. [Role of angiogenesis inhibitors in the treatment of colorectal cancer].
    Bodoky G
    Magy Onkol; 2007; 51(2):139-44. PubMed ID: 17660870
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [VEGF and its receptors as therapeutic target in cancer therapy].
    Gisterek I; Kornafel J
    Przegl Lek; 2006; 63(3):155-7. PubMed ID: 16967703
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravitreal bevacizumab for treatment of choroidal neovascularization in pathologic myopia.
    Tewari A; Dhalla MS; Apte RS
    Retina; 2006; 26(9):1093-4. PubMed ID: 17151505
    [No Abstract]   [Full Text] [Related]  

  • 40. VEGF trap as a novel antiangiogenic treatment currently in clinical trials for cancer and eye diseases, and VelociGene- based discovery of the next generation of angiogenesis targets.
    Rudge JS; Thurston G; Davis S; Papadopoulos N; Gale N; Wiegand SJ; Yancopoulos GD
    Cold Spring Harb Symp Quant Biol; 2005; 70():411-8. PubMed ID: 16869778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.